Cipla

Cipla, a Pharmaceutical Preparation Manufacturing company based in India, has established several climate commitments. For the reporting year 2026, Cipla reported Scope 1 emissions of approximately 38.4 million kg CO2e and Scope 2 emissions of about 85.9 million kg CO2e. In the preceding year, 2025, Scope 1 emissions were approximately 38.3 million kg CO2e and Scope 2 emissions were around 129.1 million kg CO2e. The company's emissions for 2024 were approximately 37.4 million kg CO2e for Scope 1 and 207.2 million kg CO2e for Scope 2. In 2023, Cipla's Scope 1 emissions were approximately 38.4 million kg CO2e, and Scope 2 emissions were about 195.8 million kg CO2e.

Cipla has set ambitious targets to reduce its environmental impact. The company aims to achieve carbon neutrality for its India manufacturing operations by December 2025, focusing on increased use of renewable energy, biomass, and energy efficiency initiatives. Furthermore, Cipla has a target to reduce its Scope 1 emissions by 30% from 2020 levels by 2030. In line with this, they also aim to reduce Scope 2 emissions by 30% from 2020 levels by 2030. Some reports indicate an aim to reduce Scope 1 and Scope 2 emissions to near zero by 2025. For the fiscal year 2024-25, an 80% reduction in absolute Scope 1 and Scope 2 emissions was targeted from 2019 levels. Cipla also aims for water neutrality and zero waste to landfill for its India manufacturing operations by December 2025.

It's important to note that Scope 3 emissions data is not currently available, with "purchased goods and services" being a noted missing data point.